Inhibitory effects for GZMA in cancer were seen mainly in the RTK (19%) pathway, with some inhibitory effects in the Hormone AR (9%), PI3K/AKT (9%), TSC/mTOR (9%), Cell Cycle (6%), and DNA Damage (6%) pathways. This evidence concerns the gene MTOR and cancer.